Ultra-low dose PET scan for PSMA
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a very low-dose PET scan to see if it can find prostate cancer cells that have PSMA on their surface. It might help you avoid higher radiation doses while still getting important images.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Women who could become pregnant must have a negative pregnancy test and cannot be breastfeeding.
- You must not have already received too much radiation from other research scans this year (more than 50 mSv).
- You must be able to lie still for a PET scan without severe claustrophobia, chronic pain, or muscle/bone issues.
- You cannot be taking a PSMA-targeted therapy (like lutetium-177) during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a very low dose of a radioactive tracer (18F-flurpiridaz) for PET scans of the heart. It aims to see if using less radiation still produces clear images, which may be safer for patients who need repeated scans.
This study tests if a very low dose of a standard PET scan tracer (FDG) can produce clear images. It may help people who need a PET scan but are concerned about radiation exposure.
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
This study tests a special PET scan (fluciclovine) to see if it can better detect prostate cancer that has low PSMA levels or has changed to a neuroendocrine type. It may help find tumors that standard PSMA scans miss.
This trial will test if a special PET scan (18F-DCFPyL) can help doctors plan your treatment with a radioactive medicine called 177Lu-vipivotide tetraxetan. You are eligible if you already qualify for that standard therapy and have had a prior PSMA PET scan showing at least one active cancer site.
This trial tests a PET scan (flotufolastat F 18) to find tiny prostate cancer cells in men whose PSA is very low but still rising after prostate removal. It may help guide further treatment decisions.
Hear when a new Prostate CA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.